Skip to main content
27 February 2021
Last updated:
Friday 26 February 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Regenerative Medicine

Positive data for Kymriah in follicular lymphoma

Tuesday 4 August 2020
Country

Switzerland

The chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel) has delivered positive data in a Phase 2 study of patients with relapsed or refractory follicular lymphoma, the second most common form of non-Hodgkin lymphoma, Novartis announced on 4 August. The global ELARA trial met its primary endpoint of complete response rate as assessed by an independent review committee. No new safety signals were observed.

Read more

Further positive data for ReNeuron cell therapy

Monday 6 July 2020
Country

United Kingdom

ReNeuron Group Plc has reported further positive long-term data for its cell therapy for retinitis pigmentosa (RP), a group of hereditary eye diseases that can lead to the progressive loss of sight and ultimately blindness. Data from a Phase 2a trial continued to show a meaningful clinical effect from the therapy at all intervals in time from the first treatment, and for the time, out to 18 months.

Read more

Freeline closes Series C financing round

Sunday 5 July 2020
Country

United Kingdom

The gene therapy developer Freeline Therapeutics Ltd has closed a $120 million extended Series C financing round in order to bring its lead programme for haemophilia B into a pivotal trial. Simultaneously on 30 June, it announced a possible initial public offering (IPO) of its shares in the US. The timing and the terms of such an offer have not been decided. Freeline’s majority shareholder is Syncona Ltd, formerly part of the Wellcome Trust.

Read more

New UK funding for gene therapy

Sunday 10 May 2020
Country

United Kingdom

The UK Medical Research Council, a public body, and LifeArc, an independent charity, are making £16 million available to establish a network of centres that will offer clinical grade viral vectors and translational and regulatory guidance to support academic-led patient trials of new gene therapies.

Read more

Santhera to research gene replacement therapy

Sunday 10 May 2020
Country

Switzerland

Switzerland-based Santhera Pharmaceuticals Holding AG is to work with Peter Yurchenco of Rutgers University, US on a novel gene therapy approach for treating a congenital muscular dystrophy caused by mutations in the LAMA2 gene. Santhera has entered into two agreements, the first with the university and the second with Prof Yurchenco, to research gene replacement as a therapy for LAMA2-related muscular dystrophy.

Read more

Bone Therapeutics extends financial runway

Sunday 10 May 2020
Country

Belgium

Belgium-based Bone Therapeutics SA has extended its financial runway into the second quarter of 2021 after negotiating equity, bond and loan deals that yielded €15 million in new capital. The proceeds will be used to advance two lead assets for bone health into late-stage development.

Read more

BioMarin moves into cardiology

Sunday 10 May 2020
Country

United Kingdom

BioMarin Pharmaceutical Inc has taken steps to extend its footprint in gene therapy with a preclinical collaboration with Dinaqor AG of Switzerland to develop therapies for rare genetic cardiomyopathies. Cardiomyopathies are diseases of the heart muscle, a significant proportion of which are inherited. Dinaqor will received an undisclosed upfront payment from BioMarin and is eligible for development, regulatory and commercial milestones. BioMarin is also investing in the Swiss company.

Read more

SwanBio raises new money for gene therapy

Saturday 25 April 2020
Country

United States

US-based SwanBio Therapeutics Inc has raised an additional $52 million in an expanded Series A financing to advance a candidate gene therapy for the inherited neurological disorder adrenomyeloneuropathy (AMN). The new financing brings the total raised in the round to $77 million. It will enable to company to conduct studies leading up to a first clinical trial as well as build up its manufacturing capacity.

Read more

Sangamo to license technology from Mogrify

Wednesday 22 April 2020
Country

United Kingdom

Sangamo Therapeutics Inc is to exclusively license cellular conversion technology from UK-based Mogrify Ltd in order to develop allogeneic cell therapies for the treatment of inflammatory and autoimmune diseases. The two companies announced the agreement on 21 April, but did not disclose the size of the upfront and milestone payments.

Read more

Evotec enters gene therapy

Tuesday 7 April 2020
Country

Germany

Evotec SE has set up a gene therapy research and development site in Austria, broadening its drug discovery capabilities to include advanced therapies as well as small molecules and biologics. The company announced the new site on 6 April, while simultaneously disclosing a contract with Takeda Pharmaceutical Co Ltd to generate gene therapies for the Japanese company’s four therapeutic areas: oncology, rare diseases, neuroscience and gastroenterology.

Read more

Pagination

  • Previous page ‹‹
  • Page 2
  • Next page ››
Subscribe to Regenerative Medicine

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Microbiotica expands management team
Wednesday February 10 2021
Philippe Dro joins Scenic Biotech as independent chairman
Wednesday February 10 2021
NOXXON announces senior appointment to its new advisory board
Wednesday February 10 2021
Wendy Levin joins Biofidelity as chief medical officer
Wednesday February 10 2021
VarmX appoints Gerard Short as chief medical officer
Wednesday February 10 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.